

Serial No 09/730,525, filed December 5, 2000

Docket No. 20757USDIV6

Page 7 of 7

REMARKS

With entry of these amendments, claims 15-23 and 26-33 are pending.

New claims 26-33 are supported throughout the specification as filed, for instance in Examples 38 and 43-45. No new matter has been added by these amendments.

New claims 26-33 correspond to claims of issued U.S. patent 6,512,162 ("the '162 patent"). New claim 26 corresponds substantially to claim 1 of the '162 patent; new claim 27 corresponds exactly to claim 4 of the '162 patent; new claim 28 corresponds exactly to claim 5 of the '162 patent; new claim 29 corresponds exactly to claim 6 of the '162 patent; new claim 30 corresponds substantially to claim 7 of the '162 patent; new claim 31 corresponds exactly to claim 10 of the '162 patent; new claim 32 corresponds exactly to claim 11 of the '162 patent; and new claim 33 corresponds exactly to claim 13 of the '162 patent.

It is believed that no Extension of Time is required. However, if it is deemed that any other fees are necessary to maintain pendency of this application, then the Office is hereby authorized to charge Deposit Account No. 50-1744 (in the name of Syngenta) for payment of such fees.

Respectfully submitted,


Mary Kakefuda

Syngenta Biotechnology, Inc.
P. O. Box 12257
3054 Cornwallis Road
Research Triangle Park, NC 27709-2257
Telephone: 919-765-5071

Attorney for Applicants
Registration No. 39,245

Date: September 11, 2003

BEST AVAILABLE COPY